vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 29,400 shares, the days-to-cover ratio is presently 0.8 days.
Institutional Investors Weigh In On vTv Therapeutics
A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned about 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors.
vTv Therapeutics Trading Up 2.9 %
Shares of VTVT opened at $14.66 on Friday. The business’s 50-day moving average price is $14.73 and its 200-day moving average price is $15.19. vTv Therapeutics has a twelve month low of $8.03 and a twelve month high of $30.99.
Wall Street Analyst Weigh In
Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective for the company.
View Our Latest Research Report on VTVT
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Recommended Stories
- Five stocks we like better than vTv Therapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- Industrial Products Stocks Investing
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Overbought Stocks Explained: Should You Trade Them?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.